Artificial intelligence is revolutionizing drug development, significantly reducing the time it takes to bring life-saving ...
A new compound, called VU319, has delivered promising results in a Phase 1 trial for treating Alzheimer’s disease and other neudegenerative conditions. The corresponding study was published in ACS ...
The MarketWatch News Department was not involved in the creation of this content.-- Commercial sponsorship integrates EvE Bio's growing field--defining "pharmome" map - 385,572 ri ...
Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...
ELRIG Drug Discovery 2025 recognizes BubbleFect, a lipid-free cell delivery system that utilizes phase separation peptides for non-viral gene therapy delivery.
Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...
Discover how DAOs revolutionize drug discovery through decentralized funding, transparency, and community governance.
SAN DIEGO, Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services ...
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the first patient has ...
Shaperon Inc. (KOSDAQ: 378800) a clinical-stage biotechnology company specializing in GPCR19-targeted immunomodulatory drugs, announced that it attended the 7 th Inflammasome Therapeutics Summit held ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback